The targeted liposomal system (termed aLip) was characterized by activatable cell-penetrating ability by responding to a tumor-associated enzyme legumain; aLip thus could enhance tumor delivery efficiency and achieve deep intratumor penetration (Figure 3A). The gene discussed is LGMN; the disease is neoplasm.